FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a new acid dihydrogenphosphate of 2-(3-{6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidine-4-yl}phenyl)-2-methylpropionic acid of formula
optionally in a crystalline form exhibiting cAMP inhibitor properties. Also, the invention refers to a pharmaceutical composition.
EFFECT: compound can find application for treating the diseases associated with cell expression of prostaglandin D2 in such diseases, as allergic rhinitis, bronchial asthma, allergic conjunctivitis, etc.
3 cl, 12 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINOPYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2007 |
|
RU2431631C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | 2009 |
|
RU2503672C2 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | 2006 |
|
RU2426733C2 |
| HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | 2008 |
|
RU2451019C2 |
| PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | 2010 |
|
RU2572608C2 |
| AMINE SALTS OF CRTH2 ANTAGONIST | 2008 |
|
RU2468013C2 |
| DP ANTAGONIST | 2019 |
|
RU2803243C2 |
| APPLICATION OF CRTH2 ANTAGONISTS IN THERAPY | 2004 |
|
RU2412934C2 |
| PHENYLACETIC ACID COMPOUNDS | 2008 |
|
RU2470926C2 |
Authors
Dates
2011-05-27—Published
2006-10-12—Filed